S1P1 and S1P3 are potential markers of cardiac microangiopathy in diabetes

Medical Hypotheses

Volumn 79, Issue 2, 2012, Pages 168-170

  Yin, Zhiyong ^a   Fan, Linni ^a   Jia, Hongbing ^b   Li, Congye ^a   Zhang, Rongqing ^a   Wang, Haichang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Infectious Diseases   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR SUBTYPE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 3; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC PATIENT; HUMAN; HYPERGLYCEMIA; MICROANGIOPATHY; MICROVASCULATURE; MOLECULAR IMAGING; PREVALENCE; TISSUE SPECIFICITY;

BIOLOGICAL MARKERS; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; HUMANS;

EID: 84863310860     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.04.025     Document Type: Article

References (28)

1. Holman N., Forouhi N.G., Goyder E., Wild S.H. The Association of Public Health Observatories (APHO) Diabetes Prevalence Model: estimates of total diabetes prevalence for England, 2010-2030. Diabet Med 2011, 28:575-582.
2. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101.
3. Saadi H., Carruthers S.G., Nagelkerke N., Al-Maskari F., Afandi B., Reed R., et al. Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates. Diabetes Res Clin Pract 2007, 78:369-377.
4. N.D. Clearinghouse, National Diabetes Statistics 2011, National Institute of Health, USA, http://www.diabetes.niddk.nih.gov.
5. Laakso M. Heart in diabetes: a microvascular disease. Diabetes Care 2011, 34(Suppl. 2):S145-S149.
6. Rosenson R.S., Fioretto P., Dodson P.M. Does microvascular disease predict macrovascular events in type 2 diabetes?. Atherosclerosis 2011, 218:13-18.
7. Wei L., Yin Z., Yuan Y., Hwang A., Lee A., Sun D., et al. A PKC-beta inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats. Microvasc Res 2010, 80:158-165.
8. Wei L., Sun D., Yin Z., Yuan Y., Hwang A., Zhang Y., et al. A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats. Apoptosis 2010, 15:488-498.
9. Del Canizo Gomez F.J., Fernandez Perez C., Moreno Ruiz I., de Gorospe Perez-Jauregui C., Silveira Rodriguez B., Gonzalez Losada T., et al. Microvascular complications and risk factors in patients with type 2 diabetes. Endocrinol Nutr 2011, 58:163-168.
10. Marcovecchio M.L., Chiarelli F. Microvascular disease in children and adolescents with type 1 diabetes and obesity. Pediatr Nephrol 2011, 26:365-375.
11. Retnakaran R., Zinman B. Type 1 diabetes, hyperglycaemia, and the heart. Lancet 2008, 371:1790-1799.
12. Camici P.G., Crea F. Coronary microvascular dysfunction. N Engl J Med 2007, 356:830-840.
13. Simmons R.K., Echouffo-Tcheugui J.B., Griffin S.J. Screening for type 2 diabetes: an update of the evidence. Diabetes Obes Metab 2010, 12:838-844.
14. Gillies C.L., Lambert P.C., Abrams K.R., Sutton A.J., Cooper N.J., Hsu R.T., et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008, 336:1180-1185.
15. Skyler J.S., Bergenstal R., Bonow R.O., Buse J., Deedwania P., Gale E.A., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009, 119:351-357.
16. Yoon Y.S., Uchida S., Masuo O., Cejna M., Park J.S., Gwon H.C., et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005, 111:2073-2085.
17. Del Bo R., Scarlato M., Ghezzi S., Maestroni A., Sjolind L., Forsblom C., et al. VEGF gene variability and type 1 diabetes: evidence for a protective role. Immunogenetics 2006, 58:107-112.
18. Lim H.S., Lip G.Y., Blann A.D. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 2005, 180:113-118.
19. Losordo D.W., Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation 2004, 109:2487-2491.
20. Lauten A., Ferrari M., Goebel B., Rademacher W., Schumm J., Uth O., et al. Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment. Eur J Heart Fail 2011, 13:711-717.
21. Levy B.I. Microvascular plasticity and experimental heart failure. Hypertension 2006, 47:827-829.
22. McDonagh P.F., Hokama J.Y. Microvascular perfusion and transport in the diabetic heart. Microcirculation 2000, 7:163-181.
23. Waeber C., Blondeau N., Salomone S. Vascular Sphingosine-1-phosphate S1P1 and S1P3 receptors. Drug News Perspect 2004, 17:365-382.
24. Allende M.L., Proia R.L. Sphingosine-1-phosphate receptors and the development of the vascular system. Biochim Biophys Acta 2002, 1582:222-227.
25. Allende M.L., Yamashita T., Proia R.L. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 2003, 102:3665-3667.
26. Singleton P.A., Dudek S.M., Chiang E.T., Garcia J.G. Regulation of Sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB J 2005, 19:1646-1656.
27. Singleton P.A., Dudek S.M., Ma S.F., Garcia J.G. Transactivation of Sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem 2006, 281:34381-34393.
28. English D., Welch Z., Kovala A.T., Harvey K., Volpert O.V., Brindley D.N., et al. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 2000, 14:2255-2265.